An artificial-intelligence approach created at Carolina could help bring new drugs to patients quicker.
An artificial-intelligence approach created at the University of North Carolina at Chapel Hill Eshelman School of Pharmacy can teach itself to design new drug molecules from scratch and has the potential to dramatically accelerate the design of new drug candidates.
The system is called Reinforcement Learning for Structural Evolution, known as ReLeaSE, and is an algorithm and computer program that comprises two neural networks which can be thought of as a teacher and a student. The teacher knows the syntax and linguistic rules behind the vocabulary of chemical structures for about 1.7 million known biologically active molecules. By working with the teacher, the student learns over time and becomes better at proposing molecules that are likely to be useful as new medicines.
Alexander Tropsha, Olexandr Isayev and Mariya Popova, all of the UNC Eshelman School of Pharmacy, are the creators of ReLeaSE. The University has applied for a patent for the technology, and the team published a proof-of-concept study in the journal Science Advances last week.
“If we compare this process to learning a language, then after the student learns the molecular alphabet and the rules of the language, they can create new ‘words,’ or molecules,” said Tropsha. “If the new molecule is realistic and has the desired effect, the teacher approves. If not, the teacher disapproves, forcing the student to avoid bad molecules and create good ones.”
ReLeaSE is a powerful innovation to virtual screening, the computational method widely used by the pharmaceutical industry to identify viable drug candidates. Virtual screening allows scientists to evaluate existing large chemical libraries, but the method only works for known chemicals. ReLeASE has the unique ability to create and evaluate new molecules.
“A scientist using virtual screening is like a customer ordering in a restaurant. What can be ordered is usually limited by the menu,” said Isayev. “We want to give scientists a grocery store and a personal chef who can create any dish they want.”
The team has used ReLeaSE to generate molecules with properties that they specified, such as desired bioactivity and safety profiles.The team used the ReLeaSE method to design molecules with customized physical properties, such as melting point and solubility in water, and to design new compounds with inhibitory activity against an enzyme that is associated with leukemia.
“The ability of the algorithm to design new, and therefore immediately patentable, chemical entities with specific biological activities and optimal safety profiles should be highly attractive to an industry that is constantly searching for new approaches to shorten the time it takes to bring a new drug candidate to clinical trials,” said Tropsha.
The Latest on: Drug design
via Google News
The Latest on: Drug design
- ProteinQure Collaborates with AstraZeneca to Design Novel Peptide Therapeuticson July 10, 2020 at 10:52 am
ProteinQure, a leader in computational protein drug discovery, announces a collaboration with the global biopharmaceutical company AstraZeneca to apply structure-based design to the creation of ...
- Alzheimer’s disease: protective gene uncovered in human cell model – bringing promise for new drug discoverieson July 10, 2020 at 3:32 am
Having extra copies of a gene called BACE2 can slow down the development of Alzheimer's disease in human brain cells.
- U.K. megatrial outshines other drug studieson July 9, 2020 at 12:27 pm
The principal investigators of a U.K. megatrial called Recovery, which has been testing existing drugs as therapies for the new disease, the pair had just finished reviewing data from 1596 patients ...
- Ridgefielder helps design affordable ventilatoron July 9, 2020 at 2:26 am
If approval is given, the SmithVent team will complete any required modifications before submitting its design to the FDA (U.S. Food and Drug Administration) for further review. Through the CoVent-19 ...
- Helping drug-delivering particles squeeze through a syringeon July 8, 2020 at 9:57 pm
Microparticles offer a promising way to deliver multiple doses of a drug or vaccine at once, because they can be designed to release their payload at specific intervals. However, the particles, which ...
- Aldeyra Therapeutics Announces New Drug Application (NDA) Development Plans for Dry Eye Diseaseon July 7, 2020 at 5:00 am
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a clinical-stage biotechnology company focused on the development of novel therapies with the ...
- Researchers design artificial genes to sense cellular responses to drugson July 6, 2020 at 10:30 am
Researchers from Boston University School of Medicine (BUSM) have developed and implemented a new way to better understand how human cells communicate with each other, how this communication is ...
- Johnson & Johnson Cuts Price of TB Drug Bedaquiline in Poorer Countrieson July 6, 2020 at 9:11 am
Investing for Retirement: How to Design A Plan that Anticipates the Unexpected The Most Important Ages for Retirement Planning: Age 50 The Most Important Ages for Retirement Planning: Age 59 ½ ...
- Repurpose.AI partnered with LEO Pharma to accelerate drug discoveryon July 6, 2020 at 5:57 am
Repurpose.AI landed a deal with drug maker LEO Pharma to identify possible candidates for dermatology and inflammatory conditions.
via Bing News